Hologic (HOLX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tejas Savant ...

Für das Gesamtjahr gab Hologic eine eher konservative Prognose ab. Das Unternehmen erwartet ein organisches Umsatzwachstum von 4% und ein bereinigtes EPS-Wachstum von 6%, wobei beide Zahlen unter den ...

MARLBOROUGH, Mass. - Hologic, Inc. (NASDAQ:HOLX) präsentierte Quartalsergebnisse im Rahmen der Analystenschätzungen, dennoch gaben die Aktien im nachbörslichen Handel um 2% nach. Der Grund: Das Medizi ...

Hologic, Inc. HOLX reported adjusted earnings per share (EPS) of $1.01 in the fourth quarter of fiscal 2024, up 13.5% year ...

The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.

Hologic reported an in line Q4, with revenues slightly ahead due to a 3.1% beat in Diagnostics, though profitability was mixed ...

Hologic, Inc.’s HOLX Diagnostics segment, excluding COVID-19 assay and related revenues, is expected to have significantly benefited from the robust Panther utilization in its Molecular ...

Hologic Inc (HOLX) reports robust Q4 2024 results with a 4.2% revenue increase, while navigating headwinds in its Skeletal ...

Hologic, Inc. focuses on women's health, projecting $4 billion in revenue for 2024. Learn why HOLX stock remains a compelling ...

Q4 2024 Earnings Call Transcript November 4, 2024 Hologic, Inc. reports earnings inline with expectations. Reported EPS is $1 ...

Hologic (NASDAQ:HOLX – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Monday ...

Good afternoon, and welcome to the Hologic's Fourth Quarter Fiscal 2024 Earnings Conference Call. My name is Shelly, and I am your operator for today’s call. Today's conference is being recorded. All ...